Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna - Archive ouverte HAL
Pré-Publication, Document De Travail Année : 2022

Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna

Résumé

Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand name Paxlovid) can complement vaccination and non-pharmaceutical interventions (NPIs) and mitigate the epidemic rebound expected when Zero-COVID ends.
Fichier principal
Vignette du fichier
manuscriptWF_hal_V2.pdf (1.83 Mo) Télécharger le fichier
supplementaryMaterial_V1.pdf (609.5 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03770270 , version 1 (06-09-2022)
hal-03770270 , version 2 (05-10-2022)
hal-03770270 , version 3 (08-11-2022)
hal-03770270 , version 4 (24-11-2022)
hal-03770270 , version 5 (02-12-2022)

Identifiants

  • HAL Id : hal-03770270 , version 1

Citer

Antoine Brault, Cécile Tran-Kiem, Clément Couteaux, Valérie Olié, Juliette Paireau, et al.. Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna. 2022. ⟨hal-03770270v1⟩
336 Consultations
253 Téléchargements

Partager

More